Bevacizumab 400Mg belongs to drug class of angiogenesis inhibitors and works by inhibiting vascular endothelial growth factor A. This activity of bevacizumab slows down growth of new blood vessels. It is indicated for treatment of certain types of cancers including renal cell carcinoma & glioblastoma. This intravenous injection also has got approval for treating age-related macular degeneration. It shows 100% of bioavailability via IV route with average elimination half life of about 20 days. Bevacizumab 400Mg is humanized recombinant monoclonal antibody which assures targeted mode of action with good survival rate.